🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

A Global Health Concern

The sexually transmitted infection are escalating worldwide, with estimates suggesting in excess of 82 million new cases annually. Notably increased rates are reported in the African continent and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Clinical Trial Data and Global Access

Based on data released by a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The trial enrolled nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in many developing nations.

Doctors on the front lines have shared positive views. The availability of a one-pill regimen such as this is hailed as a "critical tool" for public health efforts. This is deemed crucial to reduce the burden of the disease for patients and to halt the transmission of extremely resistant gonorrhoea globally.